Forma Life Sciences has launched as an independent, operator-owned contract development and manufacturing organization (CDMO) in the U.S. The new CDMO is focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug product manufacturing.

Forma was established following BioSelective Capital’s acquisition of BioDuro. The deal included two GMP facilities in Irvine, California. Both have a long-standing regulatory track record supporting clinical and commercial oral solid dosage programs.

Integrated U.S. Based Oral Solid Dosage CDMO Platform

Forma operates two cGMP-compliant facilities in Irvine totaling more than 100,000 square feet and encompassing 27 GMP manufacturing suites. Both sites support: oral solid dosage formulation development; clinical manufacturing for Phase I-III programs; process scale-up and technical transfer; and commercial drug product manufacturing.

The combined platform has the capacity to produce more than two billion tablet and capsule units annually.

Forma provides integrated formulation development and manufacturing services for tablets and capsules from early clinical development through commercial production. The company has deep expertise in spray-dried dispersion for amorphous solid dispersion systems. It also is experience in commercial-scale fluid bed granulation and coating for modified-release and multiparticulate dosage forms. These include matrix-based controlled- and delayed-release technologies.

Leadership with Established Operating Experience

Forma’s leadership team includes former architects of the business. The company is led by Cyrus K. Mirsaidi, chairman and CEO. He previously served as chief executive of BioDuro from 2015 to 2021. Armand Amin is president and head of business operations, formerly a senior leader at BioDuro.

“For more than 30 years, this organization has supported the pharmaceutical supply chain,” said Mirsaidi. “Forma was created to preserve that operating foundation while building a focused U.S. based CDMO platform.”

Amin said, “Our industry is seeing renewed focus on domestic pharmaceutical manufacturing and supply chain resilience. Forma provides a durable, U.S. based development and manufacturing platform that pharmaceutical and biotechnology partners can rely on from clinical development through commercial supply.”

Forma Life Sciences began operations as an independent company in January 2026 and is headquartered in Irvine, California.